Bayesian adaptive designs in single ascending dose trials in healthy volunteers. (August 2014)

• Record Type: Journal Article
• Authors: Guédé, David; Reigner, Bruno; Vandenhende, Francois; Derks, Mike; Beyer, Ulrich; Jordan, Paul; Worth, Eric; Diack, Cheikh; Frey, Nicolas; Peck, Richard
• Is Part Of: British journal of clinical pharmacology. Volume 78:Number 2(2014:Aug.)
• Page Start: 393
• Page End: 400
• Publication Date: 2014-08
• Subjects: Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.12344
• Languages: English
• ISSNs: 0306-5251

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bcp12344-sec-0001" sec-type="section"> <title>Aim</title> <p>Recent publications indicate a strong interest in applying Bayesian adaptive designs in first time in humans (FTIH) studies outside of oncology. The objective of the present work was to assess the performance of a new approach that includes Bayesian adaptive design in single ascending dose (SAD) trials conducted in healthy volunteers, in comparison with a more traditional approach.</p> </sec> <sec id="bcp12344-sec-0002" sec-type="section"> <title>Methods</title> <p>A trial simulation approach was used and seven different scenarios of dose–response were tested.</p> </sec> <sec id="bcp12344-sec-0003" sec-type="section"> <title>Results</title> <p>The new approach provided less biased estimates of maximum tolerated dose (MTD). In all scenarios, the number of subjects needed to define a MTD was lower with the new approach than with the traditional approach. With respect to duration of the trials, the two approaches were comparable. In all scenarios, the number of subjects exposed to a dose greater than the actual MTD was lower with the new approach than with the traditional approach.</p> </sec> <sec id="bcp12344-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The new approach with Bayesian adaptive design shows a very good performance in the estimation of MTD and in reducing the total number of healthy subjects. It also reduces the number of subjects exposed to doses greater than the actual MTD.</p> </sec> </abstract>